Related party transactions

3 Months Ended

Mar. 31, 2023

Related party transactions

Related party transactions

11. Related-party transactions

During the three months ended March 31, 2023, the Company received scientific advisory board and other scientific advisory services from one of its prior executives, Dinah Sah, Ph.D., the Company’s former Chief Scientific Officer. The total amount of fees paid to Dr. Sah for services provided during the three months ended March 31, 2023, was $199,800. The total amount of fees paid to Dr. Sah for services provided during the three months ended March 31, 2022 was de minimis.

The Company received advisory services related to strategic planning, operations, and management from Alfred Sandrock, M.D., Ph.D., the Company’s current President and Chief Executive Officer and a member of the Company’s Board of Directors, before he commenced service in the capacity of President and Chief Executive Officer in March 2022. The total amount of fees paid to Dr. Sandrock for services provided was $60,000 for the three months ended March 31, 2022.

Under the 2019 Neurocrine Collaboration Agreement, the Company and Neurocrine have agreed to conduct research, development and commercialization activities for certain of the Company’s AAV gene therapy product candidates (Note 8). Amounts due from Neurocrine are reflected as related party collaboration receivables. As of March 31, 2023, the Company had approximately $0.3 million in related party collaboration receivables associated with the 2019 Neurocrine Collaboration Agreement.